Daniel B. Kramer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel B. Kramer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Matthew R. Reynolds
Harvard Clinical Research Institute, Boston, MA
4 shared publicationsSusan L. Mitchell
Beth Israel Deaconess Medical Center, Boston MA
3 shared publications- Aaron Seth Kesselheim
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
2 shared publications Alfred E. Buxton
Beth Israel Deaconess Medical Center, Boston MA
2 shared publicationsDan W. Brock
Beth Israel Deaconess Medical Center, Boston, MA
2 shared publicationsJohn A. Spertus
Mid-America Heart Institute, Kansas City, MO
2 shared publications
Latest Publications
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S58
Health Care Goals, Communication, and Knowledge Among Older ICD Recipients
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S58
Health Care Goals, Communication, and Knowledge Among Older ICD Recipients
- 24 April 2014
- Published by Springer Nature in Current Cardiology Reports
- Vol. 16 (6) , 1-9
Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology
Since 1976, the US Food and Drug Administration (FDA) has used the premarket approval (PMA) process to approve high-risk medical devices, including implantable cardioverter defibrillators (ICDs), coronary stents, and artificial heart valves. The PMA process is widely viewed as a rigorous evaluation of device safety and effectiveness, though recent recalls—most notably related to underperforming ICD leads—have raised concerns about whether physicians and patients should sometimes be more wary about devices approved via this pathway. The FDA must utilize a “least burdensome” approach to approve new medical devices, and many widely used device models have been approved as supplements to existing PMA-approved devices with limited clinical testing. A recent Supreme Court ruling has made it difficult for patients harmed by unsafe PMA-approved devices to seek damages in court. Cardiologists who utilize high-risk medical devices should be aware that FDA approval of new devices relies on variable levels of evidence and does not necessarily indicate improved effectiveness over existing models. Clinician and patient engagement in postmarket surveillance and comparative effectiveness research remains imperative.
- 24 April 2014
- Published by Springer Nature in Current Cardiology Reports
- Vol. 16 (6) , 1-9
Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology
Since 1976, the US Food and Drug Administration (FDA) has used the premarket approval (PMA) process to approve high-risk medical devices, including implantable cardioverter defibrillators (ICDs), coronary stents, and artificial heart valves. The PMA process is widely viewed as a rigorous evaluation of device safety and effectiveness, though recent recalls—most notably related to underperforming ICD leads—have raised concerns about whether physicians and patients should sometimes be more wary about devices approved via this pathway. The FDA must utilize a “least burdensome” approach to approve new medical devices, and many widely used device models have been approved as supplements to existing PMA-approved devices with limited clinical testing. A recent Supreme Court ruling has made it difficult for patients harmed by unsafe PMA-approved devices to seek damages in court. Cardiologists who utilize high-risk medical devices should be aware that FDA approval of new devices relies on variable levels of evidence and does not necessarily indicate improved effectiveness over existing models. Clinician and patient engagement in postmarket surveillance and comparative effectiveness research remains imperative.
- 1 February 2014
- Published by Elsevier in Heart Rhythm
- Vol. 11 (2) , 216-221
Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: Results from the NCDR®
- 1 February 2014
- Published by Elsevier in Heart Rhythm
- Vol. 11 (2) , 216-221
Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: Results from the NCDR®
- 1 July 2013
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 6 (4) , 488-497
Characteristics and Outcomes of Patients Receiving New and Replacement Implantable Cardioverter-Defibrillators
Background—: Little is known about the clinical features, procedural risks, or survival of patients receiving replacement versus new implantable cardioverter-defibrillators (ICDs). Methods and Results—: Entries in the National Cardiovascular Data Registry (NCDR) ICD Registry from 2005 through 2010 were eligible for inclusion (n=463 978). Baseline demographic data, clinical information, and procedural variables were compared between patients receiving new (n=359 993; 77.6%) and replacement (n=103 985; 22.4%) ICDs and entered into a propensity match model to determine adjusted survival rates. Patients receiving replacement ICDs were older (70.7 versus 67.5 years of age) and more likely to have atrial fibrillation (41.8% versus 31.4%; P P P P P <0.0001). Conclusions—: Patients receiving replacement ICDs are older and at greater risk for death compared with those receiving initial ICD implants. The battery life of initial ICDs is shorter than previously reported.
- 1 July 2013
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 6 (4) , 488-497
Characteristics and Outcomes of Patients Receiving New and Replacement Implantable Cardioverter-Defibrillators
Background—: Little is known about the clinical features, procedural risks, or survival of patients receiving replacement versus new implantable cardioverter-defibrillators (ICDs). Methods and Results—: Entries in the National Cardiovascular Data Registry (NCDR) ICD Registry from 2005 through 2010 were eligible for inclusion (n=463 978). Baseline demographic data, clinical information, and procedural variables were compared between patients receiving new (n=359 993; 77.6%) and replacement (n=103 985; 22.4%) ICDs and entered into a propensity match model to determine adjusted survival rates. Patients receiving replacement ICDs were older (70.7 versus 67.5 years of age) and more likely to have atrial fibrillation (41.8% versus 31.4%; P P P P P <0.0001). Conclusions—: Patients receiving replacement ICDs are older and at greater risk for death compared with those receiving initial ICD implants. The battery life of initial ICDs is shorter than previously reported.
- 21 March 2013
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (4) , 615-621
Resynchronization: Considering Device‐Based Cardiac Therapy in Older Adults
Cardiac resynchronization therapy ( CRT ) is a device‐based treatment available to select individuals with systolic heart failure ( HF ), a large proportion of whom are aged 65 and older. As the field of CRT advances, together with shifting demographics and expanded indications for implantation, there is a need for practitioners caring for older adults to understand what is and is not known about the use of CRT specifically in this population. Clinical trials demonstrating benefits for severe and mild HF have uncertain generalizability to older adults. Other studies demonstrate that device‐related complications may be more common with CRT than with simpler devices and more common in older adults. CRT clinical trials also may not adequately capture outcomes and concerns specific to older adults, including quality of life and end‐of‐life care experiences. Informed decision‐making by clinicians, policy‐makers, and patients will require greater understanding of the use and outcomes of CRT in older persons.
- 21 March 2013
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (4) , 615-621
Resynchronization: Considering Device‐Based Cardiac Therapy in Older Adults
Cardiac resynchronization therapy ( CRT ) is a device‐based treatment available to select individuals with systolic heart failure ( HF ), a large proportion of whom are aged 65 and older. As the field of CRT advances, together with shifting demographics and expanded indications for implantation, there is a need for practitioners caring for older adults to understand what is and is not known about the use of CRT specifically in this population. Clinical trials demonstrating benefits for severe and mild HF have uncertain generalizability to older adults. Other studies demonstrate that device‐related complications may be more common with CRT than with simpler devices and more common in older adults. CRT clinical trials also may not adequately capture outcomes and concerns specific to older adults, including quality of life and end‐of‐life care experiences. Informed decision‐making by clinicians, policy‐makers, and patients will require greater understanding of the use and outcomes of CRT in older persons.
- 1 November 2012
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 55 (3) , 290-299
Deactivation of Pacemakers and Implantable Cardioverter-Defibrillators
- 1 November 2012
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 55 (3) , 290-299
Deactivation of Pacemakers and Implantable Cardioverter-Defibrillators
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S106
Physician Ethical and Legal Views Regarding Deactivation of Cardiac Implantable Electrical Devices
- 31 August 2010
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 16 (8) , S106
Physician Ethical and Legal Views Regarding Deactivation of Cardiac Implantable Electrical Devices